[The results of using high-dose methotrexate in treating osteogenic sarcoma].
The interim results of the use of high-dose methotrexate with leucovorin rescue for the treatment of 26 patients with osteogenic sarcoma are discussed. Preoperative chemotherapy was followed by marked regression of primary tumor in one out of seven patients with localized disease. In that group, metastasis-free period lasted 2, 3, 10+, 12, 17+ and 24+ months. Response was observed in two out of 19 (10.6%) cases of metastases. Toxic side-effects were moderate and were mainly nausea (38.5% of patients), vomiting (26.9%), elevation of serum transaminase levels (38.5%) and fever (30.7% of cases).
Perevodchikova
N I
NI
Eremina
L A
LA
Manziuk
L V
LV
Siniukov
P A
PA
Fedenko
A N
AN
Singin
A S
AS
Moldovanova
L K
LK
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy*; D002648:Child; D004341:Drug Evaluation; D005260:Female; D005266:Femoral Neoplasms / Q000188:drug therapy; D006801:Humans; D006811:Humerus; D002955:Leucovorin / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects; D012516:Osteosarcoma / Q000188:drug therapy*; D011300:Preoperative Care; D013977:Tibia
D002955:Leucovorin; D008727:Methotrexate
Rezul'taty primeneniia vysokikh doz metotreksata pri lechenii otseogennoĭ sarkomy.